1. What are the Data on 5α-Reductase Inhibitor Treatment of Benign Prostatic Hyperplasia from Everyday Practice? 
François Desgrandchamps 
European Urology Supplements 
Volume 6, Issue 6, Pages (March 2007)
DOI: /j.eursup
Copyright © Terms and Conditions

2. Fig. 1
The proportion of patients with mild (International Prostate Symptom Score [IPSS], 0–7), moderate (IPSS, 8–19), and severe (IPSS, ≥20) symptoms at baseline and week 24 in a French open-label study of dutasteride in symptomatic benign prostatic hyperplasia [15].
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © Terms and Conditions

3. Fig. 2
Comparison of mean International Prostate Symptom Scores from a French open-label study and the phase 3 programme of dutasteride in men with symptomatic benign prostatic hyperplasia [14,15].
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © Terms and Conditions

4. Fig. 3
Mean change in quasi-American Urological Association Symptom Score over 6 yr of finasteride treatment in men with symptomatic benign prostatic hyperplasia [20]. The first year was double-blind with the subsequent 5 yr open-label.
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © Terms and Conditions

5. Fig. 4
Mean change in American Urological Association Symptom Index scores (A) and Qmax (B) from baseline over 48 mo from the open-label extension study to the phase 3 programme with dutasteride [23]. Line with striped squares=placebo/dutasteride-treated subjects (P/D); line with dotted squares=dutasteride/dutasteride-treated subjects (D/D). For panel A, *p<0.001 between treatment groups; †p<0.001 for differences for both treatment groups from month 24. For panel B, *p<0.001 between treatment groups; ‡p=0.032 between treatment groups; †p=0.042 between treatment groups; ¤p<0.001 versus month 24; §p=0.039 versus month 24; ×p=0.007 versus month 24.
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © Terms and Conditions